Ok-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
Comment
Favorite

XiaoTigger
2022-03-17

Ok

Soligenix Rises on Data from Animal Study for Booster Covid-19 Shot

Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading~9% higherin the pre-mark

Soligenix Rises on Data from Animal Study for Booster Covid-19 Shot

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment

Top
Latest

XiaoTigger
·2022-03-17
Ok
Reply
Like
Report
Fold Replies
- Bull1973:
  Ok
  2022-03-17
  Reply
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9035324788,"tweetId":"9035324788","gmtCreate":1647521379199,"gmtModify":1676534239723,"author":{"id":3581637009556119,"idStr":"3581637009556119","authorId":3581637009556119,"authorIdStr":"3581637009556119","name":"XiaoTigger","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9035324788","repostId":1189529551,"repostType":4,"repost":{"id":"1189529551","pubTimestamp":1647519852,"share":"https://www.laohu8.com/m/news/1189529551?lang=&edition=full","pubTime":"2022-03-17 20:24","market":"us","language":"en","title":"Soligenix Rises on Data from Animal Study for Booster Covid-19 Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1189529551","media":"seekingalpha","summary":"Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading~9% higherin the pre-mark","content":"<html><head></head><body><ul><li>Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading~9% higherin the pre-market Thursday after announcing data froma booster vaccination study based on its experimental COVID-19 vaccine CiVax involving non-human primates ((NHPs)).</li><li>In reaction to a booster shot of CiVax, the NHPs, which were double vaccinated seven months ago with an adenovirus COVID-19 vaccine, showed a rapid increase in neutralizing antibody responses against the virus, including Delta and Omicron variants, the company said.</li><li>The neutralizing antibody levels jumped 27-fold against the original virus and Delta strains within one week of the booster and up to 243-fold by three weeks, according to Soligenix (SNGX).</li><li>The introduction of a subunit vaccine such as CiVax, “that has been built on years of proven vaccine technology may also encourage the vaccine-hesitant,” ChiefExecutive Christopher J. Schaber remarked.</li></ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soligenix Rises on Data from Animal Study for Booster Covid-19 Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoligenix Rises on Data from Animal Study for Booster Covid-19 Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-17 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3814535-sgnx-shot-gains-on-animal-data-for-booster-covid-19-shot><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading~9% higherin the pre-market Thursday after announcing data froma booster vaccination study based on its experimental COVID-19...</p>\n\n<a href=\"https://seekingalpha.com/news/3814535-sgnx-shot-gains-on-animal-data-for-booster-covid-19-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNGX":"Soligenix, Inc."},"source_url":"https://seekingalpha.com/news/3814535-sgnx-shot-gains-on-animal-data-for-booster-covid-19-shot","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1189529551","content_text":"Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading~9% higherin the pre-market Thursday after announcing data froma booster vaccination study based on its experimental COVID-19 vaccine CiVax involving non-human primates ((NHPs)).In reaction to a booster shot of CiVax, the NHPs, which were double vaccinated seven months ago with an adenovirus COVID-19 vaccine, showed a rapid increase in neutralizing antibody responses against the virus, including Delta and Omicron variants, the company said.The neutralizing antibody levels jumped 27-fold against the original virus and Delta strains within one week of the booster and up to 243-fold by three weeks, according to Soligenix (SNGX).The introduction of a subunit vaccine such as CiVax, “that has been built on years of proven vaccine technology may also encourage the vaccine-hesitant,” ChiefExecutive Christopher J. Schaber remarked.","news_type":1},"isVote":1,"tweetType":1,"viewCount":330,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":100859931,"commentId":"100859931","gmtCreate":1647521387412,"gmtModify":1663245277665,"authorId":3581637009556119,"author":{"id":3581637009556119,"idStr":"3581637009556119","authorId":3581637009556119,"name":"XiaoTigger","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9035324788,"objectIdStr":"9035324788","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>","likeSize":0,"commentSize":1,"subComments":[{"id":100860197,"commentId":"100860197","gmtCreate":1647523346603,"gmtModify":1663245278636,"authorId":3584680402793671,"author":{"id":3584680402793671,"idStr":"3584680402793671","authorId":3584680402793671,"name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9035324788,"objectIdStr":"9035324788","type":1,"supId":100859931,"supIdStr":"100859931","prevId":0,"prevIdStr":"0","content":"Ok","text":"Ok","html":"Ok"}],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}